Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016

• Main Authors: Jiangmei Liu, Weiping Liu, Lan Mi, Xinying Zeng, Cai Cai, Jun Ma, Lijun Wang, Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology, Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology
• Format: Article
• Language: English
• Published: BMC 2019-12-01
• Series: Journal of Hematology & Oncology
• Subjects: Multiple myeloma; Incidence; Mortality; Epidemiology
• Online Access: https://doi.org/10.1186/s13045-019-0807-5

Abstract Background The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China. Methods Following the general analytical strategy used in GBD 2016, the age-, sex-, and province-specific incidence and mortality in China were analyzed. Trends in the incidence and mortality from 2006 to 2016 were evaluated. Results It was estimated that there were 16,500 new cases and 10,300 deaths of multiple myeloma in China in 2016. The age-standardized incidence rates (ASIR) and mortality rates (ASMR) per 100,000 population were 1.03 (95% UI, 0.88–1.17) and 0.67 (95% UI, 0.59–0.77) in 2016. Males had higher incidence and mortality rates than females in all age groups. An upward trend with age in incidence and mortality was observed. Higher incidence and mortality rates clustered in the developed provinces. The incidence of MM in China increased significantly from 2006 to 2016, while the mortality increased from 2006 to 2014, and remained stable from 2014 to 2016. Conclusion The burden of MM showed a heterogeneous pattern in China, which highlighted the need of tailored disease prevention and control strategies in both national and provincial levels.